After the market close today, Amgen reported adjusted earnings of $2.61 per share, higher than analysts' expectations for earnings of $2.29 per share.
Revenue rose by 4% from the same period last year to $5.54 billion, in line with analysts' estimates of $5.53 billion.
For the full year 2016, the company now expects adjusted earnings per share between $10.60 to $11, compared to its prior estimates of $10.35 to $10.75.
Amgen also raised its 2016 revenue guidance to the range of $22 billion to $22.5 billion, up from its previous view of $21.7 billion to $22.3 billion.
The Thousand Oaks, CA-based biopharmaceutical company is engaged in discovering, developing, manufacturing and delivering human therapeutics.
"2015 was an exceptional year for Amgen with six innovative new launches, strong financial performance, continued pipeline advances and improved operating margins driven by our transformation efforts," CEO Robert A. Bradway said in a statement.
Separately, TheStreet Ratings Team has a "buy" rating with a score of A- on the stock.
The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations.
Although no company is perfect, currently the team does not see any significant weaknesses which are likely to detract from the generally positive outlook.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: AMGN